Opening the filing
8-K
Item 5.08 Shareholder Director Nominations.
On
October 14, 2026, the Board of Directors of Microbot Medical Inc. (the “Company”) voted to hold its annual meeting of stockholders on December 14, 2026 (the “2026 Annual Meeting”). The exact date, time and location of the 2026 Annual Meeting will be specified in the Company’s proxy statement for the 2026 Annual Meeting. The record date for the 2026 Annual Meeting is October 15, 2026.
Because the date of the Company’s 2026 Annual Meeting has been changed by more than 30 calendar days from the anniversary of the previous year’s annual meeting, the Company is establishing a new deadline for receipt of qualified stockholder proposals submitted pursuant to Rule 14a-8 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), for inclusion in the Company’s proxy materials for the 2026 Annual Meeting.
The deadline for the receipt of any qualified stockholder proposals submitted pursuant to Rule 14a-8 under the Exchange Act shall be not later than the close of business on October 27, 2026. The Company considers this a reasonable time before the Company begins to print and send its proxy materials. Each proposal must also comply with Rule 14a-8 and the SEC’s other rules and regulations regarding the inclusion of stockholder proposals in company-sponsored proxy materials.
In addition, any qualified stockholder seeking to have a nominee to the Board of Directors to be included in the Company’s proxy materials for the 2025 Annual Meeting must provide notice to the Company of its intent to do so on a Schedule 14N and file that notice with the Securities and Exchange Commission (the “SEC”) on or before October 30, 2026.
Qualified stockholder proposals must be received by the Company at its principal executive offices located at 175 Derby St., Bld. 27, Hingham, MA 02043, addressed to the Secretary of the Company. All proposals must comply with applicable Delaware law, the rules and regulations promulgated by the SEC and the procedures set forth in the By-Laws.
Item 7.01 Regulation FD Disclosure.
On October 20, 2026, the Company disseminated a press release announcing that it has received several new patent approvals across the U.S., Japan, China and Canada, further strengthening its global intellectual property portfolio as the Company continues to expand commercial adoption of the LIBERTY ® System in the U.S. and position it for growth in key international markets as it pursues a CE Mark. As a result of these latest developments, the Company now holds 44 issued patents and 49 pending patent applications across North America, Europe, Israel, and Asia. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
The information in this Item 7.01, including the attached exhibit, is being furnished, and shall not be deemed to be filed for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language of such filing. By furnishing the information in this Current Report on Form 8-K and the attached exhibit, the Company is making no admission as to the materiality of any information in this Item 7.01 or the exhibit.
Item 9.01. Financial Statements and Exhibits.
Exhibit 99.1
Exhibit 99.1
Microbot Medical ® Granted Multiple New Patents, Further Strengthening Its Global Intellectual Property Portfolio The Company now holds 44 issued patents and 49 pending patents globally. Commercialization continues to advance across both U.S. and international markets.
HINGHAM, Mass., October 20, 2026 — Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY ® Endovascular Robotic System, announced that it has received several new patent approvals across the U.S., Japan, China and Canada, further strengthening its global intellectual property portfolio as the Company continues to expand commercial adoption of the LIBERTY ® System in the U.S. and position it for growth in key international markets as it pursues a CE Mark. As a result of these latest developments, the Company now holds 44 issued patents and 49 pending patent applications across North America, Europe, Israel, and Asia.
The patent approvals reflect the Company’s ongoing strategy to protect and maximize the value of its innovations through a growing global intellectual property portfolio. The Company believes that a strong patent estate is critical to supporting future market expansion and monetizing its novel technology.
”Our commercial growth since the launch of LIBERTY goes hand in hand with our strategy to enhance and strengthen our intellectual property portfolio while simultaneously building the global infrastructure needed to support broader market access for the LIBERTY System,”